Patent ID: 7807355
Filing Date: 2010-10-05
Classification: A61K,A61P,C07K,C12N,C12Q,G01N

Abstract:
1. A method of identifying a therapeutic for decreasing intraocular pressure raised due to frizzled related protein (FRP) overexpression comprising: contacting a trabecular meshwork cell expressing a Wnt pathway component or a frizzled related protein gene product with a test compound wherein the Wnt pathway component is a Frizzled gene product, a beta-catenin gene product, a T-Cell Factor gene product, or a glycogen synthase-kinase-3 gene product; and detecting a level or bioactivity of said Wnt pathway component or said frizzled related protein gene product in the presence of the test compound; determining that the test compound is a therapeutic for decreasing intraocular pressure, when there is an increase in the level or bioactivity of a Frizzled gene product, a beta-catenin gene product, or a T-Cell Factor gene product, or when there is a decrease in the level or bioactivity of a frizzled related protein gene product, or a glycogen synthase-kinase-3 gene product, in the presence of the test compound as compared to the level or bioactivity detected in the absence of the test compound, and testing said therapeutic for its ability to decrease intraocular pressure.